US 11,965,021 B2
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
Hong Liu, El Sobrante, CA (US); Pengbo Zhang, Fremont, CA (US); Lucas Horan, Emeryville, CA (US); Yiyang Xu, Pleasanton, CA (US); Binnaz K. Staley, San Carlos, CA (US); Lianxing Liu, San Francisco, CA (US); and Hongruo Yun, San Francisco, CA (US)
Assigned to EUREKA THERAPEUTICS, INC., Emeryville, CA (US)
Appl. No. 16/608,366
Filed by EUREKA THERAPEUTICS, INC., Emeryville, CA (US)
PCT Filed Apr. 24, 2018, PCT No. PCT/US2018/029218
§ 371(c)(1), (2) Date Oct. 25, 2019,
PCT Pub. No. WO2018/200583, PCT Pub. Date Nov. 1, 2018.
Claims priority of provisional application 62/490,580, filed on Apr. 26, 2017.
Claims priority of provisional application 62/490,578, filed on Apr. 26, 2017.
Claims priority of provisional application 62/490,576, filed on Apr. 26, 2017.
Prior Publication US 2021/0107976 A1, Apr. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/283 (2013.01); C07K 16/2833 (2013.01); C07K 16/2887 (2013.01); C07K 16/303 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 23 Claims
 
1. An immune cell comprising:
a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising:
i) an antigen binding module that specifically binds to a target antigen; and
ii) a TCR module (TCRM), wherein the TCRM comprises a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a second TCRD comprising a second TCR-TM,
wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; and
wherein the caTCR further comprises a stabilization module comprising a first stabilization domain and a second stabilization domain, wherein the stabilization module is selected from the group consisting of a CH1-CL module, a CH2-CH2 module, a CH3-CH3 module, and a CH4-CH4 module;
and
b) a chimeric signaling receptor (CSR) comprising:
i) a ligand-binding module that is capable of binding or interacting with a target ligand;
ii) a transmembrane module; and
iii) a co-stimulatory immune cell signaling module that is capable of providing a co-stimulatory signal to the immune cell,
wherein the ligand-binding module and the co-stimulatory immune cell signaling module are not derived from the same molecule, wherein the CSR lacks a functional primary immune cell signaling domain, and wherein the co-stimulatory immune cell signaling module is derived from CD30;
wherein the immune cell is a T cell.